| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Chromosome Analysis and AFP with Reflex to AchE,Fetal Hgb,and Oligo-SNP(NY)
Test Code93131
CPT Codes
88235, 88269, 88280, 82106
Physician Attestation of Informed Consent
This germline genetic test requires physician attestation that patient consent has been received if ordering medical facility is located in AK, DE, FL, GA, IA, MA, MN, NV, NJ, NY, OR, SD or VT or test is performed in MA.
Includes
If Chromosomes Analysis, Amniotic Fluid is normal, then the Chromosomal Microarray, Prenatal, ClariSure® Oligo-SNP will be performed at an additional charge. (CPT code(s): 81229).
If AFP MoM is ≥2.0, then Acetylcholinesterase and Fetal Hemoglobin will be performed at an additional charge. (CPT code(s): 82664, 83033).
If AFP MoM is ≥2.0, then Acetylcholinesterase and Fetal Hemoglobin will be performed at an additional charge. (CPT code(s): 82664, 83033).
Preferred Specimen
30 mL fresh amniotic fluid collected in a sterile tube
Minimum Volume
10 mL
Instructions
Do not reject.
Patient's age, gestational age and indication(s) for testing are necessary; please submit completed cytogenetics requisition form with information. Do not split even if AFP requested. Send all tubes to lab (supernatant for AFP will be split by cytogenetics lab).
Signed informed consent is a requirement. Amniotic fluid kit and handling instructions available upon request.
This test may be replaced by other bill codes, if the complete study cannot be performed, or if the specimen does not yield mitotically active cells for analysis; Prenatal Specimen Culture; or Cytogenetics Communication (if a communication is required).
Patient's age, gestational age and indication(s) for testing are necessary; please submit completed cytogenetics requisition form with information. Do not split even if AFP requested. Send all tubes to lab (supernatant for AFP will be split by cytogenetics lab).
Signed informed consent is a requirement. Amniotic fluid kit and handling instructions available upon request.
This test may be replaced by other bill codes, if the complete study cannot be performed, or if the specimen does not yield mitotically active cells for analysis; Prenatal Specimen Culture; or Cytogenetics Communication (if a communication is required).
Transport Container
Sterile tube
Transport Temperature
Room temperature
Specimen Stability
Specimen viability decreases during transit. Send specimens to testing lab for viability determination. Do not freeze. Do not reject.
Methodology
Culture • Microscopy • Karyotype • Chemiluminescent • Gel Electrophoresis • Immunodiffusion (ID) • Oligo-SNP Array
FDA Status
This test code is for New York patient testing. For non-New York patient testing, use test code 93029.
Reference Range
See Laboratory Report
Clinical Significance
Testing determines chromosomal status of the fetus. Numerical and structural chromosomal abnormalities can be diagnosed. Sex and the presence of more than one cell line (mosaicism) can also be determined. Indications include diagnosis of chromosome abnormalities in fetuses of women who are of advanced maternal age; had a previous child with a chromosome abnormality; parental carrier of a balanced translocation, inversion or marker chromosome; parental mosaicism and follow-up for abnormal maternal serum alpha fetoprotein or maternal screening results.
Chromosomal Microarray, Prenatal, ClariSure® Oligo-SNP - This assay may be useful for:
• Further investigation on fetuses with abnormal ultrasound findings indicating congenital malformation.
• Further definition of an imbalanced cytogenetic abnormality.
• Further investigation on equivocal cytogenetic findings.
• Attempt at characterization of supernumerary marker chromosome.
• Follow-up to a documented chromosome abnormality or genomic alteration in a sibling or a parent.
• Family history of a previous child with mental retardation and/or phenotypic abnormalities.
Chromosomal Microarray, Prenatal, ClariSure® Oligo-SNP - This assay may be useful for:
• Further investigation on fetuses with abnormal ultrasound findings indicating congenital malformation.
• Further definition of an imbalanced cytogenetic abnormality.
• Further investigation on equivocal cytogenetic findings.
• Attempt at characterization of supernumerary marker chromosome.
• Follow-up to a documented chromosome abnormality or genomic alteration in a sibling or a parent.
• Family history of a previous child with mental retardation and/or phenotypic abnormalities.
Performing Laboratory
| Quest Diagnostics Nichols Institute-San Juan Capistrano, CA |
| 33608 Ortega Highway |
| San Juan Capistrano, CA 92675-2042 |
Last Updated: November 6, 2024
